PEG-rhG-CSF
5 clinical trials
4 abstracts
5 indications
Indication
Hematological MalignancyIndication
ChemotherapyIndication
Ovarian CancerIndication
lymphomaIndication
Multiple MyelomaClinical trial
Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) on Hematopoietic Stem Cell Mobilization in Poor Mobilization Patients With Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2024-05-31
Abstract
Safety in the use of granulocyte-colony stimulating factor during concurrent chemotherapy and thoracic radiotherapy in patients with small-cell lung cancer: A meta-analysis.Org: UNICAMP - State University of Campinas, Santa Marcelina College, Afya, Unipam, Evangélica University of Goiás,
Abstract
Safety and efficacy of PEG-rhG-CSF as primary prophylaxis against neutropenia induced by combination chemotherapy regimens involving oral chemotherapy agents in gastrointestinal cancer patients: A prospective, exploratory, non-randomized controlled study.Org: Graduate School of Shanxi Medical University, First Hospital of Shanxi Medical University, Luzhou District People's Hospital, Changzhi City,
Clinical trial
The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic MalignanciesStatus: Terminated, Estimated PCD: 2020-12-31
Clinical trial
Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Clinical Study on the Effectiveness and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells for Lymphoma and Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Clinical Study on the Effectiveness and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor Injection and PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma.Status: Not yet recruiting, Estimated PCD: 2025-05-01
Abstract
Association of neutrophil/lymphocyte ratio and IFN-γ with clinical response and survival in patients with MSS/pMMR mCRC treated with anti-PD-1 and VEGF inhibitors.Org: Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai Tenth People's Hospital Chongming Branch, Department of Oncology, Shanghai Tenth People's Hospital,
Abstract
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing granulocytopenia in sarcoma patients receiving doxorubicin combined with ifosfamide: A prospective, randomized, non-inferiority phase II study.Org: Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Whhan, China, Cancer Center of Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China,